Diagnosis and Multidisciplinary Care of VHL Disease–Associated Tumors

Von Hippel-Lindau (VHL) disease is associated with a range of tumor types that require timely recognition and coordinated management. Accurate diagnosis depends on careful evaluation of clinical presentation, imaging findings, and genetic assessment, as these insights directly shape treatment decisions and long-term outcomes. Because patients with VHL disease often develop multiple tumor types across organ systems, care must extend beyond initial diagnosis to ongoing monitoring and planning for future VHL-associated manifestations. Delivering optimal patient-centered care requires seamless collaboration among specialists across disciplines. It is essential that clinicians are equipped with education on recognizing VHL-associated tumors and coordinating care across disciplines to improve early detection, treatment, and overall quality of life for affected patients.

In this second of two CE Concepts BriefCases in this series, expert faculty will discuss identifying patients with VHL disease–associated tumors based on presentation, imaging, and genetic assessment as well as engaging an interdisciplinary team of professionals to guide management decisions. Through realistic clinician–patient interactions and data-driven insights, this innovative format brings patient cases to life, helping clinicians translate evidence into coordinated strategies that improve outcomes and quality of life for people with VHL.

At the conclusion of this activity, learners will be able to better:

• Identify patients with VHL disease–associated tumors based on presentation, imaging, and genetic assessment
• Engage an interdisciplinary team of professionals for the care of patients with VHL disease or VHL-associated tumors

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

• Primary: Medical oncologists, oncology nurses, and oncology nurse practitioners (NPs) and physician associates (PAs)
• Secondary: Genetic counselors, medical geneticists, and other members of the VHL treatment team

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Iliopoulos reports the following financial relationships:

Advisory Board and Consultant: Merck & Co., Inc.

Patient Advocate reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Kashemi D. Rorie, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.